vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
TOMPKINS FINANCIAL CORP is the larger business by last-quarter revenue ($194.8M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs 143.7%). Over the past eight quarters, TOMPKINS FINANCIAL CORP's revenue compounded faster (63.6% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
ESPR vs TMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $194.8M |
| Net Profit | — | $96.2M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 71.7% |
| Net Margin | — | 49.4% |
| Revenue YoY | 143.7% | 152.7% |
| Net Profit YoY | — | 388.9% |
| EPS (diluted) | $0.32 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $194.8M | ||
| Q3 25 | $87.3M | $87.4M | ||
| Q2 25 | $82.4M | $82.6M | ||
| Q1 25 | $65.0M | $81.7M | ||
| Q4 24 | $69.1M | $77.1M | ||
| Q3 24 | $51.6M | $76.6M | ||
| Q2 24 | $73.8M | $72.7M | ||
| Q1 24 | $137.7M | $72.8M |
| Q4 25 | — | $96.2M | ||
| Q3 25 | $-31.3M | $23.7M | ||
| Q2 25 | $-12.7M | $21.5M | ||
| Q1 25 | $-40.5M | $19.7M | ||
| Q4 24 | — | $19.7M | ||
| Q3 24 | $-29.5M | $18.6M | ||
| Q2 24 | $-61.9M | $15.7M | ||
| Q1 24 | $61.0M | $16.9M |
| Q4 25 | 50.6% | 71.7% | ||
| Q3 25 | -11.4% | 35.6% | ||
| Q2 25 | 8.6% | 34.2% | ||
| Q1 25 | -34.0% | 31.6% | ||
| Q4 24 | -6.4% | 33.4% | ||
| Q3 24 | -31.0% | 32.0% | ||
| Q2 24 | 3.5% | 28.3% | ||
| Q1 24 | 52.5% | 30.4% |
| Q4 25 | — | 49.4% | ||
| Q3 25 | -35.9% | 27.1% | ||
| Q2 25 | -15.4% | 26.0% | ||
| Q1 25 | -62.2% | 24.1% | ||
| Q4 24 | — | 25.5% | ||
| Q3 24 | -57.2% | 24.3% | ||
| Q2 24 | -83.9% | 21.6% | ||
| Q1 24 | 44.3% | 23.2% |
| Q4 25 | $0.32 | $6.72 | ||
| Q3 25 | $-0.16 | $1.65 | ||
| Q2 25 | $-0.06 | $1.50 | ||
| Q1 25 | $-0.21 | $1.37 | ||
| Q4 24 | $-0.14 | $1.39 | ||
| Q3 24 | $-0.15 | $1.30 | ||
| Q2 24 | $-0.33 | $1.10 | ||
| Q1 24 | $0.34 | $1.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $132.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $938.4M |
| Total Assets | $465.9M | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $132.8M | ||
| Q3 25 | $92.4M | $193.5M | ||
| Q2 25 | $86.1M | $212.6M | ||
| Q1 25 | $114.6M | $193.1M | ||
| Q4 24 | $144.8M | $134.4M | ||
| Q3 24 | $144.7M | $132.3M | ||
| Q2 24 | $189.3M | $70.9M | ||
| Q1 24 | $226.6M | $57.1M |
| Q4 25 | $-302.0M | $938.4M | ||
| Q3 25 | $-451.4M | $788.8M | ||
| Q2 25 | $-433.5M | $761.8M | ||
| Q1 25 | $-426.2M | $741.4M | ||
| Q4 24 | $-388.7M | $713.4M | ||
| Q3 24 | $-370.2M | $719.9M | ||
| Q2 24 | $-344.2M | $674.6M | ||
| Q1 24 | $-294.3M | $667.9M |
| Q4 25 | $465.9M | $8.7B | ||
| Q3 25 | $364.0M | $8.5B | ||
| Q2 25 | $347.1M | $8.4B | ||
| Q1 25 | $324.0M | $8.2B | ||
| Q4 24 | $343.8M | $8.1B | ||
| Q3 24 | $314.1M | $8.0B | ||
| Q2 24 | $352.3M | $7.9B | ||
| Q1 24 | $373.1M | $7.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $38.9M |
| Free Cash FlowOCF − Capex | — | $31.9M |
| FCF MarginFCF / Revenue | — | 16.4% |
| Capex IntensityCapex / Revenue | 0.0% | 3.6% |
| Cash ConversionOCF / Net Profit | — | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | — | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $38.9M | ||
| Q3 25 | $-4.3M | $34.9M | ||
| Q2 25 | $-31.4M | $18.9M | ||
| Q1 25 | $-22.6M | $22.2M | ||
| Q4 24 | $-35.0M | $95.0M | ||
| Q3 24 | $-35.3M | $21.2M | ||
| Q2 24 | $-7.2M | $27.3M | ||
| Q1 24 | $53.8M | $23.2M |
| Q4 25 | — | $31.9M | ||
| Q3 25 | — | $33.9M | ||
| Q2 25 | — | $18.3M | ||
| Q1 25 | — | $20.9M | ||
| Q4 24 | — | $88.8M | ||
| Q3 24 | $-35.5M | $18.9M | ||
| Q2 24 | $-7.3M | $26.3M | ||
| Q1 24 | $53.8M | $21.9M |
| Q4 25 | — | 16.4% | ||
| Q3 25 | — | 38.8% | ||
| Q2 25 | — | 22.1% | ||
| Q1 25 | — | 25.5% | ||
| Q4 24 | — | 115.1% | ||
| Q3 24 | -68.7% | 24.7% | ||
| Q2 24 | -9.9% | 36.2% | ||
| Q1 24 | 39.0% | 30.0% |
| Q4 25 | 0.0% | 3.6% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.0% | 1.7% | ||
| Q4 24 | 0.0% | 8.1% | ||
| Q3 24 | 0.3% | 2.9% | ||
| Q2 24 | 0.1% | 1.3% | ||
| Q1 24 | 0.1% | 1.9% |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 4.82× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.74× | ||
| Q1 24 | 0.88× | 1.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
TMP
Segment breakdown not available.
